Last updated: February 25, 2026
What is the current market status for Adefovir Dipivoxil?
Adefovir dipivoxil is an antiviral drug approved primarily for the treatment of chronic hepatitis B (CHB). It is marketed under the brand name Hepsera. Its approval was granted by the U.S. Food and Drug Administration (FDA) in 2002.
The drug's market penetration has been affected by the emergence of newer nucleoside/nucleotide analogs with improved safety profiles, such as tenofovir and entecavir. As of 2023, the global hepatitis B treatment market shows low growth prospects for adefovir dipivoxil, with revenues declining due to generic competition and evolving treatment guidelines prioritizing drugs with better efficacy and fewer side effects.
What are the therapeutic and competitive fundamentals?
Therapeutic Profile:
- Indication: Chronic hepatitis B
- Mechanism: Inhibits HBV DNA polymerase, reducing viral replication
- Dosing: 10 mg orally once daily
- Efficacy: Suppresses HBV DNA levels; limited evidence for superior outcomes compared to newer drugs
- Safety: Risks of nephrotoxicity and lactic acidosis, especially with long-term use
Market Competition:
- Tenofovir (TDF/TAF): Better safety profile, higher potency
- Entecavir: Equivalent or superior efficacy, fewer renal issues
- Generic versions of adefovir: Present but with limited market share due to safety concerns
What are the key investment considerations?
Patent Status and Market Exclusivity
Adefovir dipivoxil's patent expired in multiple regions between 2012 and 2015. No recent data indicates new patents or exclusivity extensions that could protect market share.
Revenue Trends
Global sales peaked around 2006-2008, then declined as newer therapies gained approval. Recent revenues are minimal, primarily driven by generic formulations in certain developing markets.
Regulatory and Policy Environment
Guidelines from the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) favor tenofovir and entecavir due to their better safety profiles. The inclusion of adefovir dipivoxil in treatment algorithms is diminishing.
Pricing and Cost Competitiveness
Generic versions reduce prices, but reduced demand makes it uncompetitive compared to newer, more effective agents.
R&D and Development Pipeline
There are no significant ongoing R&D initiatives focused on adefovir dipivoxil. Most development efforts target next-generation antivirals and combination therapies.
What is the outlook for investors?
The outlook for investing in adefovir dipivoxil production or repurposing is poor. Market share continues to erode, with no recent patents granting exclusivity or new formulations addressing safety concerns. Although certain regional markets may still use the drug, global growth prospects are negligible.
What are the key risks?
- Obsolescence due to superior drugs
- Regulatory pressure and evolving guidelines
- Limited patent protections
- Declining patient demand in developed markets
- Price erosion from generic competition
Data Summary Table
| Aspect |
Details |
| Patent expiration |
2012-2015 (vary by region) |
| Peak global sales (2008) |
~$500 million |
| Current global sales |
<$10 million (estimated, primarily generics in developing regions) |
| First-line treatment usage |
Decreased sharply post-2010; replaced by tenofovir and entecavir |
| Safety concerns |
Nephrotoxicity, lactic acidosis |
Key Takeaways
- Adefovir dipivoxil is an older hepatitis B drug with declining market relevance.
- Market momentum favors tenofovir and entecavir due to safety and efficacy.
- Patent expirations have led to increased generic availability, further depressing prices.
- No recent R&D or patent protections prolong the drug’s commercial life.
- Investment prospects are limited outside niche markets with minimal growth potential.
FAQs
1. Can adefovir dipivoxil be repurposed for other indications?
No. Its efficacy is limited to hepatitis B, with no evidence supporting use for other viral infections.
2. Are there patent protections that could influence market monopoly?
Patents expired between 2012 and 2015; no current protections remain.
3. How does adefovir’s safety profile impact market viability?
Risks of nephrotoxicity and lactic acidosis reduce its clinical use in favor of safer alternatives.
4. Could regulatory changes revive its market?
Unlikely, as current guidelines prioritize drugs with better safety and efficacy profiles.
5. Is there potential for developing new formulations?
No significant R&D efforts are underway; focus has shifted to next-generation agents.
References
- World Health Organization. (2020). Hepatitis B Fact Sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- U.S. Food and Drug Administration. (2002). Hepsera Approval Documents.
- European Medicines Agency. (2015). Summary of Product Characteristics: Hepsera.
- GlobalData. (2022). Hepatitis B market report.
- American Association for the Study of Liver Diseases. (2022). Hepatitis B Clinical Practice Guidelines.
